All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Inhibitors of the prolyl hydroxylase (PH) domain enzyme can stabilize the hypoxia-inducible factor, which stimulates erythropoietin synthesis. Therefore, these promising novel agents are developed to treat different types of anemia associated with chronic diseases. Some orally active PH inhibitors, like roxadustat, are in advanced clinical trials.